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Abstract
There are few clinical data on the combination abacavir/lamivudine plus raltegravir. We compared the out-
comes of patients from the SPIRAL trial receiving either abacavir/lamivudine or tenofovir/emtricitabine at
baseline who had taken at least one dose of either raltegravir or ritonavir-boosted protease inhibitors. For the
purpose of this analysis, treatment failure was defined as virological failure (confirmed HIV-1 RNA ‡ 50 copies/
ml) or discontinuation of abacavir/lamivudine or tenofovir/emtricitabine because of adverse events, consent
withdrawal, or lost to follow-up. There were 143 (72.59%) patients with tenofovir/emtricitabine and 54 (27.41%)
with abacavir/lamivudine. In the raltegravir group, there were three (11.11%) treatment failures with abacavir/
lamivudine and eight (10.96%) with tenofovir/emtricitabine (estimated difference 0.15%; 95% CI - 17.90 to 11.6).
In the ritonavir-boosted protease inhibitor group, there were four (14.81%) treatment failures with abacavir/
lamivudine and 12 (17.14%) with tenofovir/emtricitabine (estimated difference - 2.33%; 95% CI - 16.10 to
16.70). Triglycerides decreased and HDL cholesterol increased through the study more pronouncedly with
abacavir/lamivudine than with tenofovir/emtricitabine and differences in the total-to-HDL cholesterol ratio
between both combinations of nucleoside reverse transcriptase inhibitors (NRTIs) tended to be higher in the
raltegravir group, although differences at 48 weeks were not significant. While no patient discontinued aba-
cavir/lamivudine due to adverse events, four (2.80%) patients (all in the ritonavir-boosted protease inhibitor
group) discontinued tenofovir/emtricitabine because of adverse events ( p = 0.2744). The results of this analysis
do not suggest that outcomes of abacavir/lamivudine are worse than those of tenofovir/emtricitabine when
combined with raltegravir in virologically suppressed HIV-infected adults.
Introduction
The efficacy of antiretroviral therapy has been im-proving over time allowing an increasing proportion of
HIV-infected patients to achieve sustained suppression of
viral replication in plasma. However, a considerable propor-
tion of patients may still need to have their otherwise suc-
cessful antiviral therapy changed because of comorbidities,
drug–drug interactions, or other safety or convenience
reasons.1,2 Regimens preferentially recommended in major
guidelines at present include a combination of two nucleoside
reverse transcriptase inhibitors (NRTIs) plus a third drug
consisting of a nonnucleoside reverse transcriptase inhibitor
(NNRTI), a ritonavir-boosted protease inhibitor (PI), or an
integrase inhibitor.3–6 These recommendations are based on
major randomized clinical trials in antiretroviral-naive pa-
tients, but not all currently used drugs have been similarly
tested in settings other than antiretroviral-naive patients or
when tested have not shown the same level of evidence.
Evidence-based guidance for the use of alternative drugs
when considering changing a virologically successful anti-
retroviral regimen is often scarce.
Abacavir/lamivudine is a currently used fixed-dose com-
bination of NRTIs, but data available with new drugs such as
raltegravir are more limited than that of tenofovir/
emtricitabine and in both cases are limited to antiretroviral-
naive patients. Because abacavir/lamivudine and tenofovir/
emtricitabine may have a different impact on comorbitities,
choosing between them could be helpful to customize the
optimal therapy. Ritonavir-boosted PIs are recommended
agents for both antiretroviral-naive and antiretroviral-
experienced patients because of their potency and high barrier
to resistance,3–6 but they may increase plasma lipids, have the
potential for clinically meaningful drug–drug interactions,
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and have been associated with an increased risk for cardio-
vascular disease.7–10 In HIV-infected adults with sustained
virological suppression on ritonavir-boosted PIs, the SPIRAL
study demonstrated that switching from ritonavir-boosted
PIs to raltegravir did not result in less efficacy and did result in
a better lipid profile at 48weeks than continuing the ritonavir-
boosted PI component.11
Although abacavir/lamivudine could be used like tenofo-
vir/emtricitabine in combination with raltegravir in virolog-
ically suppressed HIV-infected patients, there are no data
comparing the two combinations of NRTIs in this setting.
To gather further insight on the abacavir/lamivudine plus
raltegravir regimen in virologically suppressed treatment-
experienced patients, we compared the efficacy and safety
of abacavir/lamivudine to that of tenofovir/emtricitabine
when each was combined with either raltegravir or ritonavir-
boosted PIs in the SPIRAL trial.
Materials and Methods
The SPIRAL study was a 48-week, multicenter, open-label,
randomized trial in which HIV-infected adults with < 50
copies/ml of plasma HIV RNA for at least the previous 6
months on ritonavir-boosted PI-based therapy were ran-
domized (1:1) to switch from the ritonavir-boosted PI to ral-
tegravir or to continue on ritonavir-boosted PI-based therapy.
The protocol was approved by the Ethics Committee at each
center and by the Spanish Medicines Evaluation Agency.
Written informed consent was obtained from all eligible pa-
tients before randomization. The SPIRAL trial is registered
with ClinicalTrials.gov number NCT00528892. This analysis
was planned after the parent study had been finished because
abacavir/lamivudine and tenofovir/emtricitabine were the
combinations of NRTIs most commonly used in the SPIRAL
study and because of the paucity of data on the combination
of abacavir/lamivudine plus raltegravir. For the purpose of
this analysis, eligible patients were those who were receiving
either abacavir/lamivudine or tenofovir/emtricitabine at
baseline and who received at least one dose of either ralte-
gravir or ritonavir-boosted PI. Patients were already taking
the combinations of abacavir/lamivudine or tenofovir/
emtricitabine when they were included in the SPIRAL study,
and for this reason all of them were able to tolerate them. As
the analysis did not ensure the homogeneity of the baseline
characteristics between groups, comparisons in outcomes
between groups were adjusted for differences in baseline
characteristics.
Treatment failure was considered in all patients who had
virological failure or discontinued abacavir/lamivudine or
tenofovir/emtricitabine because of adverse events, consent
withdrawal, or lost to follow-up. Virological failure was de-
fined by a confirmed plasma HIV-1 RNA ‡ 50 copies/ml
during treatment, whereas patients who withdrew consent,
were lost, or switched or stopped abacavir/lamivudine or
tenofovir/emtricitabine were censored. A sensitivity analysis
for efficacy endpoints was done including all randomized
patients. Fisher’s exact test was used to compare proportions
between treatment groups. The Mann–Whitney U-test was
used for comparisons of continuous variables between
groups. For testing overall differences of abacavir/lamivu-
dine relative to tenofovir/emtricitabine and stratified by ral-
tegravir and ritonavir-boosted PI use, 95% confidence
intervals for the treatment difference were calculated by
Newcombe’s method.12 Simple comparisons were made with
use of a two-sided alpha level of 0.05. Statistical analyses were
performed with the use of SAS version 9.1.3 (SAS Institute,
Cary, NC). The sponsors of the SPIRAL trial had no role in
the study design, data collection, analysis, interpretation,
or writing of this report. Esteban Martı´nez, Judit Pich, and
Ignacio Perez had full access to all the data and had the fi-
nal responsibility for the decision to submit this report for
publication.
Results
Baseline characteristics
Of the 273 patients included in the SPIRAL study, 197
(72.16%) were included in this analysis. There were 143
(72.59%) patients treated with tenofovir/emtricitabine and 54
(27.41%) with abacavir/lamivudine. Tenofovir/emtricitabine
and abacavir/lamivudine accounted for 76.56% of the com-
binations of NRTIs used in the SPIRAL study. In the overall
population, patients taking abacavir/lamivudine were older,
had a lower prevalence of previous virological failure, and
had higher plasma levels of triglycerides, total and HDL
cholesterol than patients taking tenofovir/emtricitabine
(Table 1A). Baseline characteristics in the raltegravir and
ritonavir-boosted PI groups are shown in Table 1B. In the
population assigned to raltegravir (Table 1B), patients taking
abacavir/lamivudine were significantly older and a higher
proportion had suffered previous virological failure than
those taking tenofovir/emtricitabine.
Efficacy
There were no deaths or new AIDS-defining events. In the
overall population, there were 7/54 (12.96%) treatment fail-
ures in the abacavir/lamivudine group (three virological
failures and four abacavir/lamivudine discontinuations) and
20/143 (14%) in the tenofovir/emtricitabine group (seven
virological failures and 13 tenofovir/emtricitabine discon-
tinuations) (estimated difference - 1.02%; 95% confidence
interval - 10.30 to 11.40). In the raltegravir group, there were
3/27 (11.11%) treatment failures in the abacavir/lamivudine
group and 8/73 (10.96%) in the tenofovir/emtricitabine
group (estimated difference 0.15%; 95% confidence interval
- 17.90 to 11.6). In the ritonavir-boosted PI group, there were
4/27 (14.81%) treatment failures in the abacavir/lamivudine
group and 12/70 (17.14%) in the tenofovir/emtricitabine
group (estimated difference - 2.33%; 95% confidence interval
- 16.10 to 16.70). Additional efficacy analyses according to
prior virological failure or suboptimal therapy and a sensi-
tivity analysis including all randomized patients did not sig-
nificantly affect the overall results (data not shown).
In the overall population, there were 3/54 (5.56%) viro-
logical failures in the abacavir/lamivudine group and 7/143
(4.90%) in the tenofovir/emtricitabine group (estimated dif-
ference 0.66%; 95% confidence interval - 10.50 to 5.40). In the
raltegravir group, there were 1/27 (3.70%) virological failures
in the abacavir/lamivudine group and 3/73 (4.11%) in the
tenofovir/emtricitabine group (estimated difference - 0.41%;
95% confidence interval - 8.30 to 14.4). In the ritonavir-
boosted PI group, there were 2/27 (7.41%) virological failures
in the abacavir/lamivudine group and 4/70 (5.71%) in the
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tenofovir/emtricitabine group (estimated difference 1.69%;
95% confidence interval - 18.00 to 8.00). Again, additional
efficacy analyses according to prior virological failure or
suboptimal therapy and a sensitivity analysis including all
randomized patients did not significantly affect the overall
results (data not shown).
At 48 weeks, CD4 cells (mean – SD) increased 55.74
( – 227.70) per mm3 in the abacavir/lamivudine group and
50.14 ( – 162.47) permm3 in the tenofovir/emtricitabine group
( p= 0.5992). In the raltegravir group, CD4 cells (mean – SD)
increased 33.34 (187.86) per mm3 in the abacavir/lamivudine
group and 27.89 ( – 170.14) per mm3 in the tenofovir/
emtricitabine group ( p = 0.6794) at 48 weeks. In the ritonavir-
boosted PI group, CD4 cells (mean– SD) increased 79.92
( – 266.02) per mm3 in the abacavir/lamivudine group and
74.48 ( – 151.23) permm3 in the tenofovir/emtricitabine group
( p= 0.7329) at 48 weeks.
Safety
At 48 weeks, changes in triglycerides (mean percent change,
-17.65% vs. -18.12%, p=0.4224), total cholesterol (mean per-
cent change, -7.38% vs. -5.00%, p=0.4874), LDL cholesterol
(mean percent change, -12.22% vs. -5.33%, p=0.5291), HDL
cholesterol (mean percent change, +0.72%vs. -2.56%, p=5661),
and total-to-HDL cholesterol ratio (mean percent change, -0.49
vs. -0.17, p=0.1747)were not significantly different between the
abacavir/lamivudine and tenofovir/emtricitabine groups, re-
spectively. At 48 weeks, the proportion of patients showing tri-
glycerides >200mg/dl (n=12, 22.64% vs. n=29, 21.01%,
p=0.8449), total cholesterol >240mg/dl (n=8, 15.09% vs. n=8,
5.80%, p=0.0753), or LDL cholesterol >160mg/dl (n=1, 1.89%
vs. n=4, 2.90%, p=1) was not different between the abacavir/
lamivudine or tenofovir/emtricitabine groups, respectively.
However, the proportion of patients showing HDL cho-
lesterol < 40mg/dl at 48 weeks was significantly lower with
abacavir/lamivudine (n= 11, 20.75%) relative to that with
tenofovir/emtricitabine (n = 63, 45.65%) ( p= 0.0016). Median
changes in plasma lipids in patients receiving either abacavir/
lamivudine or tenofovir/emtricitabine in combination with
raltegravir or ritonavir-boosted PI are shown in Fig. 1. As
expected, decreases in plasma lipids were higher in patients
switching from ritonavir-boosted PIs to raltegravir than in
those continuing on ritonavir-boosted PIs. Interestingly, de-
creases in triglycerides and increases in HDL cholesterol
through the study tended to be more pronounced in patients
receiving abacavir/lamivudine than in those receiving teno-
fovir/emtricitabine, and differences in the total-to-HDL
Table 1A. Demographic and Baseline Characteristics (Abacavir/Lamivudine vs. Tenofovir/Emtricitabine)
Abacavir/lamivudine Tenofovir/emtricitabine
(n = 54) (n = 143) p-value
Age, years [median (IQR)] 46.5 (42–56) 44 (40–48) 0.0054
Female sex [n (%)] 10 (18.52) 27 (25.87) 0.48
Ritonavir-boosted protease inhibitors at entry [n (%)]
Lopinavir/ritonavir 25 (46.3) 68 (47.55)
Atazanavir/ritonavir 20 (37.04) 47 (32.87)
Fosamprenavir/ritonavir 9 (16.67) 14 (9.79)
Saquinavir/ritonavir — (0) 2 (1.4)
Darunavir/ritonavir — (0) 1 (0.7)
Tipranavir/ritonavir — (0) 1 (0.7)
Patients on their first antiretroviral regimen [n (%)] 9 (16.67) 18 (12.59) 0.48
Exposure to antiretroviral therapy (years) [median (range)] 9.17 (4–11.77) 10.13 (3.7–12.76) 0.56
Exposure to protease inhibitor-based therapy (months)
[median (range)]
28 (15.52–44.03) 29.22 (18.53–36.23) 0.92
Patients with previous suboptimal antiretroviral therapy
[n (%)]
15 (27.78) 55 (38.46) 0.18
Patients with previous virological failure [n (%)] 7 (12.96) 54 (37.76) < 0.001
Patients with previous suboptimal antiretroviral therapy
or virological failure [n (%)]
19 (35.19) 70 (48.95) 0.10
Number of previous antiretroviral regimens [median (IQR)] 4 (2–7) 5 (2–7.5) 0.71
Number of previous suboptimal antiretroviral regimens
[median (IQR)]
2 (1–2) 2 (1–3) 0.41
Number of previous virological failures [median (IQR)] 2 (1–2) 1 (1–3) 0.86
Patients with AIDS [n (%)] 25 (0.7) 71 50 0.75
CD4 cell count (cells/ml) [median (IQR)] 514.5 (375.15–779.7) 486.5 (355.5–720) 0.52
CD8 cell count (cells/ml) [median (IQR)] 761.91 (577.98–1085.76) 799 (575–1071.33) 0.946
Triglycerides (mg/dl) [median (IQR)] 193 (150.58–268) 153.5 (103–238) 0.007
Triglycerides > 200mg/dl [n (%)] 23 (42.59) 48 (33.57) 0.24
Total cholesterol (mg/dl) [median (IQR)] 219.3 (193–242) 193.5 (167.5–221) 0.001
Total cholesterol > 240mg/dl [n (%)] 14 (25.93) 17 (11.89) 0.026
LDL cholesterol (mg/dl) [median (IQR)] 129.5 (107.25–149.25) 119 (96–146) 0.20
LDL cholesterol > 160mg/dl [n (%)] 16.67 (54) 11.19 (143) 0.33
HDL cholesterol (mg/dl) [median (IQR)] 49.62 (38.85–57.31) 42.31 (34–52.7) 0.008
HDL cholesterol < 40mg/dl [n (%)] 15 (27.78) 55 (38.46) 0.18
Lipid-lowering therapy at entry [n (%)] 14 (25.93) 19 (13.29) 0.052
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cholesterol ratio between both combinations of NRTIs tended
to be higher in the raltegravir group, although differences at
48 weeks were not significant in any case (Fig. 1). Four (7.41%)
patients treated with abacavir/lamivudine and seven (4.90%)
patients treated with tenofovir/emtricitabine discontinued
lipid-lowering therapies during the study ( p= 0.4972).
The overall incidence of adverse effects was similar in the
abacavir/lamivudine (n= 33, 61.11%) and the tenofovir/em-
tricitabine (n = 82, 57.34%) groups ( p = 0.6335). Although no
patient discontinued abacavir/lamivudine due to adverse
events, four (2.80%) patients (all in the ritonavir-boosted PI
group) discontinued tenofovir/emtricitabine because of kid-
ney (progressive decrease in glomerular filtration rate, n = 3)
or bone (progressive decrease in bone mineral density, n= 1)
events ( p = 0.2744).
Discussion
This analysis of the SPIRAL trial suggests that abacavir/
lamivudine may display similar efficacy and be as well tol-
erated as tenofovir/emtricitabine when combined with ral-
tegravir in virologically suppressedHIV-infected adults. Prior
comparisons between both fixed-dose NRTI combinations in
virologically suppressed HIV-infected adults have also
shown similar results in the BICOMBO and STEAL
trials,13,14 although in the BICOMBO trial there were more
FIG. 1. Median percent change in triglycerides (A), total
cholesterol (B), LDL cholesterol (C), and HDL cholesterol
(D), and median change in total-to-HDL cholesterol ratio (E)
at different time points during the study. Black squares de-
note abacavir/lamivudine, and white squares denote teno-
fovir/emtricitabine. Continuous lines denote raltegravir,
and dashed lines denote ritonavir-boosted protease inhibi-
tors. p-values within the dashed lines refer to comparisons
between ritonavir-boosted protease inhibitor (PI/r)-con-
taining regimens and p-values within the continuous lines
refer to comparisons between raltegravir (RAL)-containing
regimens at different time points.
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discontinuations with abacavir/lamivudine due to hyper-
sensitivity because patients had not been previously tested for
HLA-B5701. In the SPIRAL study, patients taking abacavir/
lamivudine or tenofovir/emtricitabine had been taking these
combinations for months or years and therefore they were
already able to tolerate them.
Approximately 40% of treatment failures in the abacavir/
lamivudine and tenofovir/emtricitabine groups in the SPIR-
AL trial were due to virological failure. There are no available
data on the use of raltegravir combined with tenofovir/
emtricitabine or abacavir/lamivudine in other than anti-
retroviral-naive patients. In combination with tenofovir/
emtricitabine, raltegravir (n= 281) demonstrated no inferiority
when compared with efavirenz (n= 282) in the STARTMRK
study (53% of the patients had HIV-1 RNA > 100,000 copies/
ml). The proportion of patients treated with tenofovir/
emtricitabine plus raltegravir showing HIV-1 RNA < 50
copies/ml was 86% at 48 weeks, 81% at 96 weeks, and 75% at
156 weeks.15–17 Data with abacavir/lamivudine plus ralte-
gravir are more limited. The SHIELD trial (34% of the patients
had HIV-1 RNA > 100,000 copies/ml) was a prospective,
observational study enrolling 35 antiretroviral-naive patients
who initiated abacavir/lamivudine plus raltegravir. The pro-
portion of patients showing HIV-1 RNA < 50 copies/ml was
91% at 48 weeks and 77% at 96 weeks.18,19
In accordance with other studies comparing abacavir/
lamivudine and tenofovir/emtricitabine, patients taking
abacavir/lamivudine showed higher plasma lipids at baseline
as compared to patients taking tenofovir/emtricitabine.13,14,20–22
Although differences were not significant at 48 weeks, it may
be of interest that through the study decreases in triglycerides,
decreases in total-to-HDL cholesterol, and increases in HDL
cholesterol tended to be higher when raltegravir (instead of
ritonavir-boosted PIs) was combinedwith abacavir/lamivudine
than with tenofovir/emtricitabine. This was also consistent
with a significantly lower proportion of patients showing
HDL cholesterol < 40mg/dl at 48 weeks when treated with
abacavir/lamivudine compared to tenofovir/emtricitabine,
and a nonsignificant higher decrease in the total-to-HDL
cholesterol ratio at 48weeks in patients treatedwith abacavir/
lamivudine plus raltegravir relative to patients treated with
tenofovir/emtricitabine plus raltegravir.
These data suggest that the improvement in plasma lipids
expected when PIs are replaced by raltegravir in virologically
suppressed HIV-infected patients should not be worse when
the combination of NRTIs used is abacavir/lamivudine than
when it is tenofovir/lamivudine. This finding was unex-
pected and the reason is not clear. Potential explanations
might be that baseline lipids with abacavir/lamivudine were
already higher that those with tenofovir/emtricitabine when
combined with ritonavir-boosted protease inhibitors and/or
that the lipid-lowering effect of discontinuing ritonavir-
boosted protease inhibitors may be greater with abacavir/
lamivudine than with tenofovir/emtricitabine. However,
these results should be takenwith caution because of the small
sample size and the lack of significance at 48 weeks in most
lipid changes. Nevertheless, because of the paucity of data
concerning the combination of abacavir/lamivudine plus
raltegravir and because the design of the SPIRAL study in-
cluded only antiretroviral-experienced, virologically sup-
pressed HIV-infected patients, it would make sense to
accurately investigate the lipid profile in future studies as-
sessing the effects of this antiretroviral combination in other
patient settings.
There were no discontinuations of any combination of
NRTIs due to adverse events when combined with ralte-
gravir. In patients taking ritonavir-boosted PIs, four patients
discontinued tenofovir/emtricitabine due to adverse events
as compared to no patient discontinuing abacavir/lamivu-
dine. Although this difference was not significant, the results
are not unexpected due to the negative impact of protease
inhibitors on tenofovir-related kidney or bone toxicity.23,24
The small sample size of the abacavir-lamivudine group is
a limitation of the study. However, the only existing data on
the combination abacavir/lamivudine plus raltegravir in-
cluded 35 antiretroviral-naive patients, and thus the number
of patients with this combination of interest was almost
double in our study. The NRTI backbone was not the ran-
domized component, although comparisons in outcomes
were adjusted for baseline characteristics showing differences
between groups. In addition, the analyses of efficacy out-
comes may have been affected by the reduced power given to
the relatively low frequency of the outcome measures. How-
ever, the study has also strengths as there are few data on the
combination abacavir/lamivudine plus raltegravir and the
data available are restricted to antiretroviral-naive patients.
In summary, this analysis of the SPIRAL trial does not
suggest that outcomes of abacavir/lamivudine are worse
than those of tenofovir/emtricitabine when combined with
raltegravir in virologically suppressed HIV-infected adults.
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